EPCCS 2018 An impression of the presentation of Prof. Richard McManus on the evidence of thresholds, the difference in guidelines and the role of the GP, given during the Annual EPCCS CV Summit.
EPCCS 2018 Slides prepared and presented by Dr. M.C. van der Wel (Nijmegen), here offered as an educational service.
EPCCS 2018 Slides prepared and presented by Prof. Richard McManus (Oxford, UK), here offered as an educational service.
In the SPRINT study, a diastolic threshold of <55 mmHg was associated with increased cardiovascular events in both patients with and without cardiovascular disease.
ACC 2018 Black barbershops and pharmacists worked together to improve high BP in non-hispanic black men. In a randomized design, a pharmacist intervention led to 27 mmHg drop in SBP over 6 months, vs. 9 mmHg in controls.
Lifestyle importantly contributes to preventable morbidity and mortality. This EPCCS guidance document outlines the presented evidence on ingredients of successful behaviour change strategies and motivational interviewing, as well as which CV risk behaviours and clinical outcomes may be improved with various types of strategies.
AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods.
AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing in the BP measurement changed the treatment effect.
Although midlife hypertension is more common in men, it was only associated with the risk of dementia in women, suggesting that hypertension is a modifiable risk factor for dementia in women.
In a SPRINT-eligible ACCORD-BP population, a high-risk cohort of diabetic patients, intensive BP control at a goal of <120 mmHg, reduced CVD outcomes.
Individuals previously considered “metabolically healthy obese” are still at higher CV risk compared with normal weight metabolically healthy persons, according to a large UK health record dataset.
ESC 2017 Posthoc SPRINT analysis shows that persons with SBP ≥160 mmHg and low Framingham risk score, have a higher risk of all-cause mortality with intensive treatment.